

10/516971

5 Rec'd PCT/PTO 03 DEC 2004

PATENT

Attorney Docket No.: 082398-000110US

Client Reference No.: E1-A0304P-US

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

YOSHIKAWA et al.

Application No.: Not yet assigned

Filed:

U.S. National Phase of: PCT/JP03/07010

Int'l Filing Date: June 3, 2003

For: NOVEL CONDENSED
IMIDAZOLE DERIVATIVES

Examiner: Not yet assigned

Art Unit: Not yet assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

References "AE" - "AH", "AK" and "AL" were cited by the International Search Authority in the corresponding PCT application. A English translation of the Search/Examination report in the corresponding PCT application is enclosed.


Document "AK" is not in the English language. Document "AK" (Beljean-Leymarie, 1983) is categorized as an "A" document on the attached International Search Report.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Kevin Bastian
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KLB:ath
60369634 v1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/516 971
		Filing Date	
		First Named Inventor	Yoshikawa, Seiji
		Art Unit	Not yet assigned
Examiner Name	Not yet assigned		
Attorney Docket Number	082398-000110US		
Sheet	1	of	

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	2002/0161001 A1	10/31/2002	Kanstrup et al.	
	AB	2002/0198205 A1	12/26/2002	Himmelsbach et al.	
	AC	2004/0082570 A1	04/29/2004	Yoshikawa et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AD	WO	00/56296	A2/A3	09/28/2000	Ferring BV		<input type="checkbox"/>
	AE	WO	02/02560	A2	01/10/2002	Novo Nordisk A/S		<input type="checkbox"/>
	AF	WO	02/068420	A1	09/06/2002	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>
	AG	WO	03/004496	A1	01/16/2003	Novo Nordisk A/S		<input type="checkbox"/>
	AH	EP	0 206 415	A2	12/30/1986	Janssen Pharmaceutica N.V.		<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./

Examiner Signature	/Cecilia Jaisle/	Date Considered	07/01/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60369634 v1

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/516971
		Filing Date	
		First Named Inventor	Yoshikawa, Seiji
		Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Sheet 2 of	Attorney Docket Number	082398-000110US	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AI	BALKAN, B. et al.; "Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats"; <u>Diabetologia</u> ; 1999; pp. 1324-1331; Vol. 42; Springer-Verlag	
	AJ	BAUVOIS, B. et al.; "Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia"; <u>British Journal of Cancer</u> ; 1999; pp. 1042-1048; Vol. 79, No. 7/8; Cancer Research Campaign	
	AK	BELJEAN-LEYMARIE, Martine et al.; "Hydrazines et hydrazones hétérocycliques. IV. Synthèses de dérivés de l'hydrazine dans la série des imidazo[4,5-d] pyridazinones-4"; <u>Can. J. Chem.</u> ; 1983; pp. 2563-2566; Vol. 61	
	AL	BERRY, David A. et al.; "Synthesis of 8-amino-3-deazaguanine via imidazole precursors. Antitumor activity and inhibition of purine nucleoside phosphorylase"; <u>J. Med. Chem.</u> ; 1986; pp. 2034-2037; Vol. 29	
	AM	CALLEBAUT, Christian et al.; "T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4 ⁺ cells"; <u>Science</u> ; December 24, 1993; pp. 2045-2050; Vol. 262	
	AN	GOTOH, Hiroshi et al.; "Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients"; <u>Clin Chem.</u> ; 1988; pp. 2499-2501; Vol. 34, No. 12.	
	AO	HARTMANN, B. et al.; "Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagons-like peptide-2 in rats and mice"; <u>Endocrinology</u> ; 2000; pp. 4013-4020; Vol. 141, No. 11; The Endocrine Society; USA	
	AP	HOLST, Jens J. and Carolyn F. Deacon; "Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for Type 2 diabetes"; <u>Diabetes</u> ; November 1998; pp. 1663-1670; Vol. 47	
	AQ	KOHL, A. et al.; "The role of dipeptidylpeptidase IV positive T cells in wound healing and angiogenesis"; <u>Agents and Actions</u> ; 1991; pp. 125-127; Vol. 32, No. 1/2; Birkhäuser Verlag; Basel	
	AR	STEINBRECHER, Andreas et al.; "Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF- β 1 secretion <i>in vivo</i> "; <u>The Journal of Immunology</u> ; 2001; pp. 2041-2048; Vol. 166	
	AS	WILSON, Michael J. et al.; "Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands"; <u>Journal of Andrology</u> ; March/April 2000; pp. 220-226; Vol. 21, No. 2	
	AT	YIP, Rupert G. C. and M. Michael Wolfe; "GIP biology and fat metabolism"; <u>Life Sciences</u> ; 2000; pp. 91-103; Vol. 66, No. 2	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.J./

Examiner Signature	/Cecilia Jaiste/	Date Considered	07/01/2008
--------------------	------------------	-----------------	------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.